Gubra CEO Sees Potential for GUB-UCN2 in Multiple Indications
Gubra's CEO has highlighted the potential for the company's drug candidate GUB-UCN2 to be applied across several different medical indications.
Stocks · News reference
Gubra Issues Reminder for Upcoming Investor R&D Event
Gubra A/S has issued a reminder regarding its scheduled Investor R&D Event, which is set to take place on October 27, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading